The Chimeric antigen receptor (CAR) T-cell therapy is a form of adaptive cellular therapy in which a patient's T cells are isolated, genetically modified and infused back in the patients body to recognise and kill the cancer cells, said Dr Mayank Singh, Additional Professor in the Department of Medical Oncology at Dr B R Ambedkar Institute Rotary Cancer Hospital, (BRAIRCH), AIIMS here.
Doctors at AIIMS, Delhi are in the process of developing a low cost antibody-based adaptive cellular therapy for treatment of multiple myeloma, a form of blood cancer.
This kind of therapy is expected to make advanced treatments like CAR-T cell therapies more affordable and accessible for patients in India.
The story "Aiims in process of making low cost therapy for treating multiple myeloma" has 776 words across 26 sentences, which will take approximately 4 - 7 minutes for the average person to read.
Which news outlet covered this story?
The story "Aiims in process of making low cost therapy for treating multiple myeloma" was covered 14 hours ago by Business Standard, a news publisher based in India.
How trustworthy is 'Business Standard' news outlet?
Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news.
The outlet is headquartered in India and publishes an average of 119 news stories per day.
It's most recent story was published 2 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Negative, indicating that people regard this as "bad news".
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
